<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="editorial"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38116001</article-id><article-id pub-id-type="pmc">PMC10728869</article-id><article-id pub-id-type="doi">10.3389/fimmu.2023.1339263</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Editorial</subject></subj-group></subj-group></article-categories><title-group><article-title>Editorial: Immunology of cachexia</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kumar</surname><given-names>Vijay</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/523585"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Stewart</surname><given-names>John H.</given-names><suffix>IV</suffix></name><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<institution>Department of Surgery, Laboratory of Tumor Immunology and Immunotherapy, Morehouse School of Medicine</institution>, <addr-line>Atlanta, GA</addr-line>, <country>United States</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited and Reviewed by: Giamila Fantuzzi, University of Illinois Chicago, United States</p></fn><corresp id="fn001">*Correspondence: John H. Stewart IV, <email xlink:href="mailto:jstewart@msm.edu">jstewart@msm.edu</email>; Vijay Kumar, <email xlink:href="mailto:vijkumar@msm.edu">vijkumar@msm.edu</email>; <email xlink:href="mailto:vij_tox@yahoo.com">vij_tox@yahoo.com</email>
</corresp><fn fn-type="other" id="fn003"><p>&#x02020;ORCID: Vijay Kumar, <uri xlink:href="https://orcid.org/0000-0001-9741-3597">orcid.org/0000-0001-9741-3597</uri>
</p></fn></author-notes><pub-date pub-type="epub"><day>05</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><elocation-id>1339263</elocation-id><history><date date-type="received"><day>15</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>28</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2023 Kumar and Stewart</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Kumar and Stewart</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><related-article related-article-type="commentary-article" id="RA1" xlink:href="https://www.frontiersin.org/research-topics/47456" ext-link-type="uri">Editorial on the Research Topic <article-title>Immunology of cachexia</article-title>
</related-article><kwd-group><kwd>cachexia</kwd><kwd>immunity</kwd><kwd>inflammation</kwd><kwd>NLRP3 inflammasome</kwd><kwd>cancer</kwd><kwd>immune-checkpoint inhibitors</kwd></kwd-group><counts><fig-count count="0"/><table-count count="0"/><equation-count count="0"/><ref-count count="36"/><page-count count="4"/><word-count count="1556"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Cancer Immunity and Immunotherapy</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Cachexia manifests as a chronic inflammatory condition with profound weight loss that includes muscle wasting/sarcopenia with or without loss of adipose/fat mass (<xref rid="B1" ref-type="bibr">1</xref>). It is more common in patients with chronic infections, such as acquired immunodeficiency syndrome (AIDS, a human immunodeficiency virus (HIV)-1 infection) and tuberculosis (caused by <italic>mycobacterium tuberculosis</italic> infection), chronic inflammatory diseases, and many aggressive cancers (gastrointestinal and lung cancers) (<xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>). Cancer-associated cachexia (CAC) cannot be easily differentiated from anorexia or other causes of weight or muscle loss. Therefore, CAC is considered as a multifactorial syndrome characterized by ongoing skeletal muscle loss, with or without fat loss and can be partially but not entirely reversed by conventional nutrition support (<xref rid="B6" ref-type="bibr">6</xref>). CAC is responsible for 30% of all cancer deaths, although cachexia is not prevalent in all cancer types (<xref rid="B7" ref-type="bibr">7</xref>). Furthermore, CAC increases with cancer metastasis, which proves lethal to patients due to failed therapeutic breakthrough to reverse CAC and decreased efficacy of available immunotherapeutics and chemotherapeutics (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). Furthermore, altered immune responses that support tumor growth and metastasis also play critical roles in the development of cachexia. These findings support further investigation (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). Therefore, the current Research Topic entitled &#x0201c;<italic>Immunology of cachexia</italic>&#x0201d; is a step in this direction.</p><p>
<ext-link xlink:href="https://doi.org/10.3389/fimmu.2021.729182" ext-link-type="uri">de Cassia Rosa de Jesus et&#x000a0;al.</ext-link> discuss the heterogenous expression of the NOD-like receptor (NLR) family pyrin domain containing 3 (NLRP3) that forms inflammasomes upon activation and induces IL-1&#x003b2; and IL-18 secretion to create a pro-inflammatory environment in the adipose tissue (AT) of colorectal cancer (CC) patients. These patients have different comorbidities, including systemic arterial hypertension (seen most frequently). Their study has shown increased systemic inflammation (decreased circulating albumin and increased C-Reactive Protein (CRP) levels) in patients with CC who present with cachexia (defined as per the international consensus criteria) as compared to the control group (<xref rid="B1" ref-type="bibr">1</xref>). They further found NLRP3 overexpression in the subcutaneous adipose tissues (scAT) of patients with CC compared to control and weight-stable patients with CC (WSC). They observed similar findings in the visceral adipose tissue (VAT) close to the tumor (peritumoral adipose tissue, PtAT) of patients with CC who present with cachexia. The scAT of patients with CC-associated cachexia and WSC overexpress caspase-1 (CASP-1), a critical component of NLRP3 inflammasome relative to the control group. However, <italic>in vitro</italic> studies associated with lipopolysaccharide (LPS) stimulation in scAT and ptAT have variable results due to dysregulated TLR expression and function. Hence, further research in this area is warranted to establish the immunoregulatory role of NLRP3 inflammasomes in CAC. Furthermore, NLRP3 inflammasome activation plays a role in hypertension therefore further studies in different cells, including immune cells are critical to establish the role of NRLP3 inflammasome activation in CC cachexia without hypertension (<xref rid="B11" ref-type="bibr">11</xref>&#x02013;<xref rid="B13" ref-type="bibr">13</xref>).</p><p>
<ext-link xlink:href="https://doi.org/10.3389/fimmu.2021.730070" ext-link-type="uri">Sun et&#x000a0;al.</ext-link> have shown that the Institute of Cancer Research (ICR) mice develop skeletal muscle loss/atrophy in response to continuous IL-6 infusions in their tibialis anterior muscles via immune receptor activation and metabolic energy reduction. For example, IL-6 infusion downregulates several genes involved in oxidative phosphorylation (OXPHOS) and tricarboxylic acid (TCA) or Krebs cycle and supports aerobic glycolysis to support pro-inflammatory immunometabolic reprograming (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). Furthermore, glycolysis also supports NLRP3 inflammasome activation to aggravate the inflammation and skeletal muscle cell pyroptosis (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). They have further shown that signal transducer and activator of transcription 3 (STAT3), NF-&#x003ba;B, tumor protein 53 (TP53 or p53), and myogenin (MyoG) signaling in response to IL-6 are critical for cachexia-associated muscle atrophy. Hence, IL-6 via glycolysis may activate NLRP3 inflammasome in skeletal muscle and fat cells of patients with cancer to induce cachexia.</p><p>
<ext-link xlink:href="https://doi.org/10.3389/fimmu.2022.999084" ext-link-type="uri">Sun et&#x000a0;al.</ext-link> have shown the differential expression of necroptosis-related genes (NRGs) in patients with CC and help to classify patients into high and low-risk groups. Furthermore, necroptosis mediates muscle protein degradation in a cachexia model and proteins that signal for necroptosis can activate NLRP3 inflammasome (<xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B20" ref-type="bibr">20</xref>). Thus, NLRP3 inflammasome activation through different interconnected pro-inflammatory signaling events serves as a critical mediator of the CAC. Hence, future studies that delineate necroptosis and immune reprograming in CAC are needed. Furthermore, the study by <ext-link xlink:href="https://doi.org/10.3389/fimmu.2022.1074440" ext-link-type="uri">Pinci et&#x000a0;al.</ext-link> in the Research Topic has indicated that tumor necrosis factor (TNF), released by the activation of a disintegrin and metalloproteinase (ADAM proteases), serves as a necroptosis-associated alarmin. The increased TNF levels support cachexia by increasing the loss of AT and proteolysis and decreasing protein, lipid, and glycogen synthesis, along with its pro-inflammatory action (<xref rid="B21" ref-type="bibr">21</xref>). Therefore, TLR and NLRP3 activation-mediated pro-inflammatory events are critical players in the immunopathogenesis of cachexia and need further investigation.</p><p>
<ext-link xlink:href="https://doi.org/10.3389/fimmu.2023.1253587" ext-link-type="uri">Cunningham et&#x000a0;al.</ext-link> investigated the platelet status in cancer cachexia progression by using Apc<sup>Min/+</sup> mice. This study indicates that platelet numbers increase before cachexia development and can become activated during its progression. In the pre-cachexia stage, these mice showed elevated levels of transforming growth factor &#x003b2;2 (TGF&#x003b2;2), TGF&#x003b2;3, Mothers against decapentaplegic homolog 3 or SMAD family member 3 (SMAD3), and IL-1&#x003b2; overexpression in their skeletal muscles. The Apc<sup>Min/+</sup> mice with severe cachexia overexpressed Ly6G, CD206 (mannose receptor), and IL-10 mRNA. The pre-cachectic Apc<sup>Min/+</sup> mice show decreased physical activity and anemia that increases with the cachexia severity. Earlier clinical study has indicated a negative association between platelet count and one-year overall survival of patients with cancer cachexia (<xref rid="B22" ref-type="bibr">22</xref>). Furthermore, increased platelet count is associated with renal cachexia and cardiovascular mortality in end-stage renal disease patients (<xref rid="B23" ref-type="bibr">23</xref>). Hence, understanding the immunological functions of platelets in cachexia is important. For example, NLRP3 inflammasome activation in platelets is a critical pro-inflammatory event for multi-organ injury and platelets also regulate the NRLP3 inflammasome activation in other immune cells, such as macrophages and neutrophils by licensing The NLRP3 transcription (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Therefore, it will be interesting to observe the platelet mediated NLRP3 inflammasome regulation in myeloid immune cells (MICs), myocytes, and adipocytes of patients with CAC.</p><p>
<ext-link xlink:href="https://doi.org/10.3389/fimmu.2023.1197112" ext-link-type="uri">Minagawa et&#x000a0;al.</ext-link> have shown that deleting the transformed follicular lymphoma (TFL) gene induces extraordinary C-X-C chemokine ligand 13 (CXCL13 or B cell-attracting chemokine 1or BCA-1) secretion and cachexia development in transgenic VavP-<italic>Bcl2</italic> mice, thus causing early death. CXCL13 is a ligand for CXCR5 (Burkitt&#x02019;s lymphoma receptor 1 or BLR1) and controls B cell development and trafficking (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>). Hence, this study indicates that CXCL13 overexpression and cachexia development in lymphoma occur downstream of TFL activity. Further studies will&#x000a0;help to understand the immunological role of CXCL13 and&#x000a0;TFL in other cancers and associated cachexia. Therefore, innate and adaptive immune components play a critical role in&#x000a0;the immunology of CAC depending on the tumor type and&#x000a0;stage, comprising a novel therapeutic approach for immunotherapeutic targeting.</p><p>Immune checkpoint inhibitors (ICIs) are the latest immunotherapies available to patients with cancer. The review by <ext-link xlink:href="https://doi.org/10.3389/fimmu.2022.1070961" ext-link-type="uri">Li et&#x000a0;al.</ext-link> discuss the advanced hepatocellular carcinoma (AHCC) tumor immune microenvironment (TIME) and role of PD-1/PD-L1 checkpoint inhibitors alone or in different combinations along with&#x000a0;associated challenges. Furthermore, a clinical case report by <ext-link xlink:href="https://doi.org/10.3389/fimmu.2022.1073094" ext-link-type="uri">Li et&#x000a0;al.</ext-link> suggests the efficacy of S-1 and Oxaliplatin (SOX) chemotherapy with anti-PD-1 and invariant natural killer T (iNKT) cell immunotherapies in a patient with stage IV gastric adenocarcinoma with liver metastasis. Patients with Stage IV gastric&#x000a0;adenocarcinoma with liver metastasis develop severe cachexia. Therefore, the cachexia index (CXI) can serve as a good prognostic marker in patients with gastric cancer (GC) and CC (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>) This is applicable to patients with low CXI, particularly those&#x000a0;combined with cachexia, low body mass index (BMI) or advanced stage cancer (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). Therefore, CXI has the potential to serve as a predictive marker for metastatic GC and efficacy of immunotherapeutic agents. Furthermore, <ext-link xlink:href="https://doi.org/10.3389/fimmu.2022.1074906" ext-link-type="uri">Jia et&#x000a0;al.</ext-link> in their clinical trial data, have indicated the efficacy of sintilimab in combination with autologous NK cells as a second-line treatment for patients with advanced non-small cell lung cancer (NSCLC). Cachexia is a negative prognostic indicator in patients receiving second line systemic chemotherapy (<xref rid="B30" ref-type="bibr">30</xref>). Therefore, it is important to observe the impact of autologous NK cell-based immunotherapy on cachexia in patients with advanced cancers and vice versa.</p><p>Cachexia influences the efficacy of ICIs, such as PD-1/PD-L1 inhibitors in advanced cancers. For example, cachexia in patients with advanced NSCLC reduces the efficacy of PD-1/PD-L1 checkpoint inhibitors (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). Therefore, predicting the risk of cachexia development in advanced cancers, including advanced NSCLC and AHCC, before the starting ICIs has a potential to improve clinical outcomes (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>).</p><p>In the last article of the Research Topic, <ext-link xlink:href="https://doi.org/10.3389/fimmu.2023.1207746" ext-link-type="uri">Robinson et&#x000a0;al.</ext-link> have discussed the impact of inflammation and acute phase activation in cancer cachexia. For example, emerging studies indicate the presence of intact regulatory type 2 immunity (abundant IL-33 and eotaxin-2 level) in the visceral adipose tissue (VAT) of experimental and clinical cases of CC and pancreatic cancer-associate cachexia (<xref rid="B35" ref-type="bibr">35</xref>). Furthermore, local macrophages in the VAT are also critical for cachexia-induced fat loos in patients with cancer, including HCC (<xref rid="B36" ref-type="bibr">36</xref>). Therefore, cachexia, including CAC pathogenesis involves dysregulated immune response and suggests further research to understand the immunology of cachexia and designing novel immune-based biomarkers and therapeutics.</p><sec sec-type="author-contributions" id="s1"><title>Author contributions</title><p>VK: Conceptualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. JS: Writing &#x02013; review &#x00026; editing.</p></sec></body><back><sec sec-type="COI-statement" id="s2"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p></sec><sec sec-type="disclaimer" id="s3"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Evans</surname><given-names>WJ</given-names></name><name><surname>Morley</surname><given-names>JE</given-names></name><name><surname>Argil&#x000e9;s</surname><given-names>J</given-names></name><name><surname>Bales</surname><given-names>C</given-names></name><name><surname>Baracos</surname><given-names>V</given-names></name><name><surname>Guttridge</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Cachexia: a new definition</article-title>. <source>Clin Nutr</source> (<year>2008</year>) <volume>27</volume>:<page-range>793&#x02013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.clnu.2008.06.013</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keithley</surname><given-names>JK</given-names></name><name><surname>Swanson</surname><given-names>B</given-names></name></person-group>. <article-title>HIV-associated wasting</article-title>. <source>J Assoc Nurses AIDS Care</source> (<year>2013</year>) <volume>24</volume>(<issue>1 Suppl</issue>):<page-range>S103&#x02013;111</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jana.2012.06.013</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheung</surname><given-names>WW</given-names></name><name><surname>Paik</surname><given-names>KH</given-names></name><name><surname>Mak</surname><given-names>RH</given-names></name></person-group>. <article-title>Inflammation and cachexia in chronic kidney disease</article-title>. <source>Pediatr Nephrol</source> (<year>2010</year>) <volume>25</volume>:<page-range>711&#x02013;24</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00467-009-1427-z</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>EA</given-names></name><name><surname>Cheung</surname><given-names>WW</given-names></name><name><surname>Toma</surname><given-names>KG</given-names></name><name><surname>Mak</surname><given-names>RH</given-names></name></person-group>. <article-title>Muscle wasting in chronic kidney disease</article-title>. <source>Pediatr Nephrol</source> (<year>2018</year>) <volume>33</volume>:<page-range>789&#x02013;98</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00467-017-3684-6</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baracos</surname><given-names>VE</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><name><surname>Korc</surname><given-names>M</given-names></name><name><surname>Guttridge</surname><given-names>DC</given-names></name><name><surname>Fearon</surname><given-names>KCH</given-names></name></person-group>. <article-title>Cancer-associated cachexia</article-title>. <source>Nat Rev Dis Primers</source> (<year>2018</year>) <volume>4</volume>:<fpage>17105</fpage>. doi: <pub-id pub-id-type="doi">10.1038/nrdp.2017.105</pub-id>
<pub-id pub-id-type="pmid">29345251</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fearon</surname><given-names>K</given-names></name><name><surname>Strasser</surname><given-names>F</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Bosaeus</surname><given-names>I</given-names></name><name><surname>Bruera</surname><given-names>E</given-names></name><name><surname>Fainsinger</surname><given-names>RL</given-names></name><etal/></person-group>. <article-title>Definition and classification of cancer cachexia: an international consensus</article-title>. <source>Lancet Oncol</source> (<year>2011</year>) <volume>12</volume>:<page-range>489&#x02013;95</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(10)70218-7</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siff</surname><given-names>T</given-names></name><name><surname>Parajuli</surname><given-names>P</given-names></name><name><surname>Razzaque</surname><given-names>MS</given-names></name><name><surname>Atfi</surname><given-names>A</given-names></name></person-group>. <article-title>Cancer-mediated muscle cachexia: etiology and clinical management</article-title>. <source>Trends Endocrinol Metab</source> (<year>2021</year>) <volume>32</volume>:<fpage>382</fpage>&#x02013;<lpage>402</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.tem.2021.03.007</pub-id>
<pub-id pub-id-type="pmid">33888422</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Biswas</surname><given-names>AK</given-names></name><name><surname>Acharyya</surname><given-names>S</given-names></name></person-group>. <article-title>Understanding cachexia in the context of metastatic progression</article-title>. <source>Nat Rev Cancer</source> (<year>2020</year>) <volume>20</volume>:<page-range>274&#x02013;84</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41568-020-0251-4</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Argil&#x000e9;s</surname><given-names>JM</given-names></name><name><surname>L&#x000f3;pez-Soriano</surname><given-names>FJ</given-names></name><name><surname>Stemmler</surname><given-names>B</given-names></name><name><surname>Busquets</surname><given-names>S</given-names></name></person-group>. <article-title>Cancer-associated cachexia &#x02014; understanding the tumour macroenvironment and microenvironment to improve management</article-title>. <source>Nat Rev Clin Oncol</source> (<year>2023</year>) <volume>20</volume>:<page-range>250&#x02013;64</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41571-023-00734-5</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>Y-e</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name></person-group>. <article-title>Immunoregulation in cancer-associated cachexia</article-title>. <source>J Adv Res</source> (<year>2023</year>) <volume>S2090-1232</volume>(<issue>23</issue>):<page-range>00124&#x02013;128</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jare.2023.04.018</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bartoli-Leonard</surname><given-names>F</given-names></name><name><surname>Zimmer</surname><given-names>J</given-names></name><name><surname>Sonawane</surname><given-names>AR</given-names></name><name><surname>Perez</surname><given-names>K</given-names></name><name><surname>Turner</surname><given-names>ME</given-names></name><name><surname>Kuraoka</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>NLRP3 inflammasome activation in peripheral arterial disease</article-title>. <source>J Am Heart Assoc</source> (<year>2023</year>) <volume>12</volume>:<elocation-id>e026945</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/JAHA.122.026945</pub-id>
<pub-id pub-id-type="pmid">36892058</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pasqua</surname><given-names>T</given-names></name><name><surname>Pagliaro</surname><given-names>P</given-names></name><name><surname>Rocca</surname><given-names>C</given-names></name><name><surname>Angelone</surname><given-names>T</given-names></name><name><surname>Penna</surname><given-names>C</given-names></name></person-group>. <article-title>Role of NLRP-3 inflammasome in hypertension: A potential therapeutic target</article-title>. <source>Curr Pharm Biotechnol</source> (<year>2018</year>) <volume>19</volume>:<page-range>708&#x02013;14</page-range>. doi: <pub-id pub-id-type="doi">10.2174/1389201019666180808162011</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>SM</given-names></name><name><surname>Ling</surname><given-names>YH</given-names></name><name><surname>Huuskes</surname><given-names>BM</given-names></name><name><surname>Ferens</surname><given-names>DM</given-names></name><name><surname>Saini</surname><given-names>N</given-names></name><name><surname>Chan</surname><given-names>CT</given-names></name><etal/></person-group>. <article-title>Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension</article-title>. <source>Cardiovasc Res</source> (<year>2018</year>) <volume>115</volume>:<page-range>776&#x02013;87</page-range>. doi: <pub-id pub-id-type="doi">10.1093/cvr/cvy252</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ando</surname><given-names>M</given-names></name><name><surname>Uehara</surname><given-names>I</given-names></name><name><surname>Kogure</surname><given-names>K</given-names></name><name><surname>Asano</surname><given-names>Y</given-names></name><name><surname>Nakajima</surname><given-names>W</given-names></name><name><surname>Abe</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Interleukin 6 enhances glycolysis through expression of the glycolytic enzymes hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3</article-title>. <source>J Nippon Med Sch</source> (<year>2010</year>) <volume>77</volume>:<fpage>97</fpage>&#x02013;<lpage>105</lpage>. doi: <pub-id pub-id-type="doi">10.1272/jnms.77.97</pub-id>
<pub-id pub-id-type="pmid">20453422</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>Q</given-names></name><name><surname>Xi</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhuang</surname><given-names>Q</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer</article-title>. <source>Int J Oncol</source> (<year>2016</year>) <volume>48</volume>:<page-range>215&#x02013;24</page-range>. doi: <pub-id pub-id-type="doi">10.3892/ijo.2015.3225</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>PKM2-dependent glycolysis promotes skeletal muscle cell pyroptosis by activating the NLRP3 inflammasome in dermatomyositis/polymyositis</article-title>. <source>Rheumatol (Oxford)</source> (<year>2021</year>) <volume>60</volume>:<page-range>2177&#x02013;89</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/rheumatology/keaa473</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation</article-title>. <source>Nat Commun</source> (<year>2016</year>) <volume>7</volume>:<fpage>13280</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ncomms13280</pub-id>
<pub-id pub-id-type="pmid">27779186</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Necroptosis mediates muscle protein degradation in a cachexia model of weanling pig with lipopolysaccharide challenge</article-title>. <source>Int J Mol Sci</source> (<year>2023</year>) <volume>24</volume>(<issue>13</issue>):<elocation-id>10923</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms241310923</pub-id>
<pub-id pub-id-type="pmid">37446099</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kang</surname><given-names>TB</given-names></name><name><surname>Yang</surname><given-names>SH</given-names></name><name><surname>Toth</surname><given-names>B</given-names></name><name><surname>Kovalenko</surname><given-names>A</given-names></name><name><surname>Wallach</surname><given-names>D</given-names></name></person-group>. <article-title>Activation of the NLRP3 inflammasome by proteins that signal for necroptosis</article-title>. <source>Methods Enzymol</source> (<year>2014</year>) <volume>545</volume>:<fpage>67</fpage>&#x02013;<lpage>81</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/B978-0-12-801430-1.00003-2</pub-id>
<pub-id pub-id-type="pmid">25065886</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Conos</surname><given-names>SA</given-names></name><name><surname>Chen</surname><given-names>KW</given-names></name><name><surname>De Nardo</surname><given-names>D</given-names></name><name><surname>Hara</surname><given-names>H</given-names></name><name><surname>Whitehead</surname><given-names>L</given-names></name><name><surname>N&#x000fa;&#x000f1;ez</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner</article-title>. <source>Proc Natl Acad Sci</source> (<year>2017</year>) <volume>114</volume>:<page-range>E961&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1073/pnas.1613305114</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patel</surname><given-names>HJ</given-names></name><name><surname>Patel</surname><given-names>BM</given-names></name></person-group>. <article-title>TNF-&#x003b1; and cancer cachexia: Molecular insights and clinical implications</article-title>. <source>Life Sci</source> (<year>2017</year>) <volume>170</volume>:<fpage>56</fpage>&#x02013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lfs.2016.11.033</pub-id>
<pub-id pub-id-type="pmid">27919820</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Ruan</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Association between platelet count with 1-year survival in patients with cancer cachexia</article-title>. <source>J Cancer</source> (<year>2021</year>) <volume>12</volume>:<page-range>7436&#x02013;44</page-range>. doi: <pub-id pub-id-type="doi">10.7150/jca.62788</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Molnar</surname><given-names>MZ</given-names></name><name><surname>Streja</surname><given-names>E</given-names></name><name><surname>Kovesdy</surname><given-names>CP</given-names></name><name><surname>Budoff</surname><given-names>MJ</given-names></name><name><surname>Nissenson</surname><given-names>AR</given-names></name><name><surname>Krishnan</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>High platelet count as a link between renal cachexia and cardiovascular mortality in end-stage renal disease patients</article-title>. <source>Am J Clin Nutr</source> (<year>2011</year>) <volume>94</volume>:<page-range>945&#x02013;54</page-range>. doi: <pub-id pub-id-type="doi">10.3945/ajcn.111.014639</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rolfes</surname><given-names>V</given-names></name><name><surname>Ribeiro</surname><given-names>LS</given-names></name><name><surname>Hawwari</surname><given-names>I</given-names></name><name><surname>B&#x000f6;ttcher</surname><given-names>L</given-names></name><name><surname>Rosero</surname><given-names>N</given-names></name><name><surname>Maasewerd</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Platelets fuel the inflammasome activation of innate immune cells</article-title>. <source>Cell Rep</source> (<year>2020</year>) <volume>31</volume>:<fpage>107615</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2020.107615</pub-id>
<pub-id pub-id-type="pmid">32402278</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cornelius</surname><given-names>DC</given-names></name><name><surname>Baik</surname><given-names>CH</given-names></name><name><surname>Travis</surname><given-names>OK</given-names></name><name><surname>White</surname><given-names>DL</given-names></name><name><surname>Young</surname><given-names>CM</given-names></name><name><surname>Austin Pierce</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>NLRP3 inflammasome activation in platelets in response to sepsis</article-title>. <source>Physiol Rep</source> (<year>2019</year>) <volume>7</volume>:<elocation-id>e14073</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.14814/phy2.14073</pub-id>
<pub-id pub-id-type="pmid">31054188</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>E</given-names></name><name><surname>F&#x000f6;rster</surname><given-names>R</given-names></name><name><surname>Wolf</surname><given-names>I</given-names></name><name><surname>Ebensperger</surname><given-names>C</given-names></name><name><surname>Kuehl</surname><given-names>WM</given-names></name><name><surname>Lipp</surname><given-names>M</given-names></name></person-group>. <article-title>The G protein-coupled receptor BLR1 is involved in murine B cell differentiation and is also expressed in neuronal tissues</article-title>. <source>Eur J Immunol</source> (<year>1993</year>) <volume>23</volume>:<page-range>2532&#x02013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1002/eji.1830231023</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Legler</surname><given-names>DF</given-names></name><name><surname>Loetscher</surname><given-names>M</given-names></name><name><surname>Roos</surname><given-names>RS</given-names></name><name><surname>Clark-Lewis</surname><given-names>I</given-names></name><name><surname>Baggiolini</surname><given-names>M</given-names></name><name><surname>Moser</surname><given-names>B</given-names></name></person-group>. <article-title>B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5</article-title>. <source>J Exp Med</source> (<year>1998</year>) <volume>187</volume>:<page-range>655&#x02013;60</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1084/jem.187.4.655</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gong</surname><given-names>C</given-names></name><name><surname>Wan</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Zuo</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>T</given-names></name></person-group>. <article-title>Cachexia index as a prognostic indicator in patients with gastric cancer: A retrospective study</article-title>. <source>Cancers (Basel)</source> (<year>2022</year>) <volume>14</volume>(<issue>18</issue>):<elocation-id>4400</elocation-id>. doi: <pub-id pub-id-type="doi">10.3390/cancers14184400</pub-id>
<pub-id pub-id-type="pmid">36139560</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wan</surname><given-names>Q</given-names></name><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Prognostic value of cachexia index in patients with colorectal cancer: A retrospective study</article-title>. <source>Front Oncol</source> (<year>2022</year>) <volume>12</volume>:<elocation-id>984459</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2022.984459</pub-id>
<pub-id pub-id-type="pmid">36212479</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Naito</surname><given-names>T</given-names></name><name><surname>Kenmotsu</surname><given-names>H</given-names></name><name><surname>Taira</surname><given-names>T</given-names></name><name><surname>Wakuda</surname><given-names>K</given-names></name><name><surname>Oyakawa</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer</article-title>. <source>Support Care Cancer</source> (<year>2015</year>) <volume>23</volume>:<page-range>1699&#x02013;708</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00520-014-2534-3</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miyawaki</surname><given-names>T</given-names></name><name><surname>Naito</surname><given-names>T</given-names></name><name><surname>Kodama</surname><given-names>A</given-names></name><name><surname>Nishioka</surname><given-names>N</given-names></name><name><surname>Miyawaki</surname><given-names>E</given-names></name><name><surname>Mamesaya</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Desensitizing effect of cancer cachexia on immune checkpoint inhibitors in patients with advanced NSCLC</article-title>. <source>JTO Clin Res Rep</source> (<year>2020</year>) <volume>1</volume>:<fpage>100020</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jtocrr.2020.100020</pub-id>
<pub-id pub-id-type="pmid">34589927</pub-id>
</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roch</surname><given-names>B</given-names></name><name><surname>Coffy</surname><given-names>A</given-names></name><name><surname>Jean-Baptiste</surname><given-names>S</given-names></name><name><surname>Palaysi</surname><given-names>E</given-names></name><name><surname>Daures</surname><given-names>J-P</given-names></name><name><surname>Pujol</surname><given-names>J-L</given-names></name><etal/></person-group>. <article-title>Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors</article-title>. <source>Lung Cancer</source> (<year>2020</year>) <volume>143</volume>:<fpage>19</fpage>&#x02013;<lpage>26</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lungcan.2020.03.003</pub-id>
<pub-id pub-id-type="pmid">32200137</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mu</surname><given-names>W</given-names></name><name><surname>Katsoulakis</surname><given-names>E</given-names></name><name><surname>Whelan</surname><given-names>CJ</given-names></name><name><surname>Gage</surname><given-names>KL</given-names></name><name><surname>Schabath</surname><given-names>MB</given-names></name><name><surname>Gillies</surname><given-names>RJ</given-names></name></person-group>. <article-title>Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors</article-title>. <source>Br J Cancer</source> (<year>2021</year>) <volume>125</volume>:<page-range>229&#x02013;39</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41416-021-01375-0</pub-id>
</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goh</surname><given-names>MJ</given-names></name><name><surname>Kang</surname><given-names>W</given-names></name><name><surname>Jeong</surname><given-names>WK</given-names></name><name><surname>Sinn</surname><given-names>DH</given-names></name><name><surname>Gwak</surname><given-names>GY</given-names></name><name><surname>Paik</surname><given-names>YH</given-names></name><etal/></person-group>. <article-title>Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy</article-title>. <source>Sci Rep</source> (<year>2022</year>) <volume>12</volume>:<fpage>7647</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-022-11736-1</pub-id>
<pub-id pub-id-type="pmid">35538112</pub-id>
</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lenehan</surname><given-names>PJ</given-names></name><name><surname>Cirella</surname><given-names>A</given-names></name><name><surname>Uchida</surname><given-names>AM</given-names></name><name><surname>Crowley</surname><given-names>SJ</given-names></name><name><surname>Sharova</surname><given-names>T</given-names></name><name><surname>Boland</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Type 2 immunity is maintained during cancer-associated adipose tissue wasting</article-title>. <source>Immunother Adv</source> (<year>2021</year>) <volume>1</volume>:<fpage>ltab011</fpage>. doi: <pub-id pub-id-type="doi">10.1093/immadv/ltab011</pub-id>
<pub-id pub-id-type="pmid">34291232</pub-id>
</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Erdem</surname><given-names>M</given-names></name><name><surname>M&#x000f6;ckel</surname><given-names>D</given-names></name><name><surname>Jumpertz</surname><given-names>S</given-names></name><name><surname>John</surname><given-names>C</given-names></name><name><surname>Fragoulis</surname><given-names>A</given-names></name><name><surname>Rudolph</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Macrophages protect against loss of adipose tissue during cancer cachexia</article-title>. <source>J&#x000a0;Cachexia Sarcopenia Muscle</source> (<year>2019</year>) <volume>10</volume>:<page-range>1128&#x02013;42</page-range>. doi: <pub-id pub-id-type="doi">10.1002/jcsm.12450</pub-id>
</mixed-citation></ref></ref-list></back></article>
